TREM1, also known as triggering receptor expressed on myeloid cells 1, is a cell surface receptor predominantly expressed on myeloid cells, including monocytes, macrophages, and neutrophils. It was first discovered in 2000 as a regulator of inflammatory responses. TYROBP, or TYRO protein tyrosine kinase-binding protein, also known as DAP12, is an adaptor protein that associates with TREM1 and mediates its signaling. Together, TREM1 and TYROBP play crucial roles in immune responses, particularly in the amplification of inflammatory reactions.
The Human TREM1-TYROBP Stable Cell Line - CHO-K1 is a cell line engineered to stably express both TREM1 and TYROBP proteins. This cell line serves as a valuable tool for studying the molecular mechanisms underlying TREM1-TYROBP signaling pathway and its involvement in inflammatory processes. CHO-K1 cells, derived from Chinese hamster ovary cells, offer advantages such as robust growth and ease of genetic manipulation, making them suitable for the expression of recombinant proteins. The establishment of this stable cell line provides researchers with a reliable model system for investigating the functional significance of TREM1-TYROBP interaction in immune modulation and inflammatory diseases.
HIV and hepatitis C virus (HCV) chronically infect approximately 35 million and 75 million people globally, respectively. Researchers investigated how HIV and HCV infections trigger inflammation in liver cells, potentially leading to diseases like Hepatocellular Carcinoma (HCC). They found that HIV and HCV stimulate innate immune responses in liver-resident macrophages, including increased expression of Triggering Receptor Expressed on Myeloid cells 1 (TREM1). TREM1 amplifies immune signaling, exacerbating inflammation. Targeting TREM1 signaling could offer therapeutic opportunities to reduce HIV-induced liver inflammation.
Figure 1. A stable cell line overexpressing TREM1 was generated by researchers through lentiviral transduction of THP1 cells to assess the function of TREM1 signaling during viral exposure. TREM1 mRNA expression was confirmed by qPCR analysis, and cell surface expression was validated using flow cytometry. (Hyun J, et al., 2019)
1. Inflammatory Response Studies: Assess the role of TREM1-TYROBP complex in modulating inflammatory responses through cytokine profiling and NF-κB activation assays.
2. Drug Screening: Utilize the cell line to screen potential therapeutics targeting TREM1-TYROBP interaction in inflammatory diseases like sepsis.
3. Immune Cell Interaction Analysis: Investigate the impact of TREM1-TYROBP signaling on immune cell interactions via co-culture experiments with macrophages or neutrophils.
4. Pathogen Interaction Studies: Explore how pathogens exploit TREM1-TYROBP axis by infecting CHO-K1 cells expressing the stable complex.
5. Gene Expression Profiling: Employ RNA sequencing to decipher the downstream gene expression changes mediated by TREM1-TYROBP signaling pathway.
6. In Vivo Efficacy Evaluation: Assess the therapeutic potential of compounds identified through in vitro studies using animal models of inflammatory diseases.
Customer Q&As
Why were HEK293T cells chosen for establishing the stable NECTIN4 cell line?
A: HEK293T cells were likely selected for their high transfection efficiency and suitability for stable transgene expression, facilitating the study of NECTIN4 biology and its role in cell adhesion, signaling, and cancer progression.
How was the stability of NECTIN4 expression confirmed and maintained in this HEK293T stable cell line?
A: Stability was likely assessed through methods such as flow cytometry, immunoblotting, or functional assays measuring NECTIN4-mediated signaling, with continuous selection pressure applied.
Can you describe the characterization of NECTIN4 expression in the HEK293T stable cell line, including its localization and interaction partners?
A: Characterization may involve analysis of NECTIN4 membrane localization, interaction with binding partners such as nectins or afadin, downstream signaling pathways, and functional implications in cell adhesion, migration, or cancer metastasis.
What quality control measures were employed during the generation of this stable cell line?
A: Quality control likely included confirmation of NECTIN4 expression levels, validation of its functional activity, assessment of off-target effects, and validation of phenotypic changes associated with NECTIN4 modulation.
How do the observed functional properties of NECTIN4 in this stable cell line relate to its physiological roles and relevance in cancer biology and potential therapeutic targeting?
A: Comparative analysis with primary epithelial cells or in vivo models helps validate the relevance of NECTIN4 expression in cancer initiation, progression, and metastasis, guiding the development of NECTIN4-targeted therapeutics for cancer treatment.
Ask a Question
Customer Reviews
Reliable TREM1-TYROBP Stable Cell Line
Unmatched consistency! The Human TREM1-TYROBP Stable Cell Line in CHO-K1 cells delivers reliable TREM1-TYROBP expression, ensuring robust results in my immunology research.
Empowering innate immune studies
Empowering advanced studies! With stable TREM1-TYROBP expression, I can explore innate immune responses and inflammation mechanisms with confidence, driving scientific breakthroughs.
Exceptional performance in immune modulation
Exceptional performance! This cell line exceeds expectations, providing a solid foundation for investigating TREM1-TYROBP-targeted therapies and immune modulation strategies.
United Kingdom
08/28/2022
Streamlined experimental workflows
Streamlining research processes! Its stable expression streamlines experimental workflows, enhancing efficiency and enabling in-depth data analysis with ease.
Indispensable asset for immune signaling research
An indispensable asset! The Human TREM1-TYROBP Stable Cell Line has revolutionized my research, offering valuable insights into TREM1-TYROBP-mediated immune signaling and potential therapeutic interventions.
United Kingdom
04/04/2020
Write a Review